The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | The growing importance of monoclonal antibodies in transplant-eligible & ineligible myeloma
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the important role of monoclonal antibodies (mAbs) in the treatment of multiple myeloma. Daratumumab-based combinations have transformed outcomes for patients with transplant-eligible and ineligible disease, and Dr Ramasamy further comments on the value of using these agents in clinical practice. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
